ABOUT CENCORA
Cencora combines core pharmaceutical distribution with innovative business solutions to help our partners across the healthcare spectrum get medications to the patients who need them. Biopharmaceutical companies benefit from the global scale and resources of a company ranked #10 on the Fortune 500, combined with local expertise provided by more than 51,000 team members worldwide. Learn more at www.cencora.com.
Cencora has a proven history of bringing complex, transformative cell and gene therapies (CGTs) to market on a global scale. With end-to-end expertise in global strategies and key local markets, Cencora is ready to deliver strategic guidance along with implementation support across a broad array of functional areas. As a connected partner, Cencora is committed to navigating the patient and treatment journeys together with CGT manufacturers, no matter where they are in development.
CELL & GENE THERAPIES
Your therapy can make all the difference. Together, we'll unlock its potential.
CONTACT INFORMATION
Cencora
1 W 1st Ave.
Conshohocken, PA 19428
UNITED STATES
FEATURED INSIGHTS
-
![GettyImages-657049072 vaccine, pharma]( "Best Practices For Managing The Logistics And Distribution Of CGTs")
Site infrastructure, formulary timelines, and storage capabilities create barriers between approval and patient access. Planning for these operational realities separates successful launches from stalled ones.
-
![GettyImages-1248237924 IV]( "Navigating EU Regulatory Challenges With Cell And Gene Therapies")
EU regulatory changes affecting advanced therapies demand new approaches to scientific advice, evidence generation, and health technology assessment for cell and gene therapy developers.
-
![GettyImages-1208552262 elderly, patient, telehealth]( "Transforming PSP Enrollment To Enhance User Experiences And Optimize Workflows")
Lengthy enrollment calls burden patients and PSP teams alike. See how a digital-first intake approach cut onboarding time and improved outcomes for everyone involved.
-
![GettyImages-2167387228 meeting, strategy]( "The Value Of Real-World Evidence In Canadian Drug Commercialization")
Leveraging real-world evidence (RWE) across the product lifecycle enables manufacturers to fill the evidence gap beyond RCTs to help guide local commercial strategic planning and market access strategy.
-
![GettyImages-1367214441 business, meeting]( "Digitized Solutions To Increase Visibility And Streamline Communication Between A PSP And Manufacturer")
When email-based escalation management creates compliance and visibility gaps, a centralized digital solution helps manufacturer and PSP teams act faster and with greater accountability.
EXPLORE OUR THOUGHT LEADERSHIP
Explore the latest insights from the Cencora team.
WHITE PAPERS
-
![Cencora - Payer Coverage white paper]( "Evolving Landscape Of Payer Coverage For CGTs: Trends And Insights")
Evolving Landscape Of Payer Coverage For CGTs: Trends And InsightsExamine how proactive payer engagement and robust clinical evidence regarding comparative effectiveness and durability of response can overcome significant reimbursement barriers and enhance patient access.
VIDEOS AND WEBINARS
-
![GettyImages-2149321181 colleagues, meeting]( "Integrated Quality, Regulatory, And Safety Services")
Integrated Quality, Regulatory, And Safety ServicesA single-vendor model for quality, regulatory, and safety services provides consistent project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.
-
![GettyImages-1204037710 meeting]( "Understanding PRCI And Its Requirements")
Understanding PRCI And Its RequirementsNavigating Health Canada's clinical information disclosure process takes real precision and preparation. Ensure your submission stays compliant, on schedule, and ready for review.
-
![Cencora CMC struggles in CGT]( "Why Manufacturing And Quality Are Critical To Meeting FDA Expectations")
Why Manufacturing And Quality Are Critical To Meeting FDA ExpectationsCMC failures are a top reason for BLA rejections in cell and gene therapy. Learn proactive strategies to spot subtle quality gaps and ensure your manufacturing aligns with strict FDA expectations.
-
![Cencora - Orchestration]( "Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order Management")
Connecting Manufacturers And Providers To The Services Needed For Full End-To-End Patient And Order ManagementStreamline complex cell and gene therapy logistics with an integrated platform that connects manufacturers with vital services, providing full visibility and control for a more efficient and successful patient journey.
-
![Strategic Logistics]( "Crafting Scalable Solutions For Maximum Reach And Success")
Crafting Scalable Solutions For Maximum Reach And SuccessIs your supply chain ready for a blockbuster cell and gene therapy launch? Industry leaders discuss selecting partners, managing risk, and scaling operations for maximum reach and success.
BLOGS
-
![GettyImages-1055095236 patient_nurse]( "Inside The Payer Perspective On Cell And Gene Therapy Coverage")
Inside The Payer Perspective On Cell And Gene Therapy CoverageFind out what 19 US payer organizations revealed about CGT coverage decisions, pre-approval engagement timelines, and the clinical evidence they need most to approve high-cost therapies.
-
![GettyImages-2235582013-prefilled-syringe-liquid-manufacturing]( "The Need For Adaptive Distribution Partners For Cell And Gene Therapies")
The Need For Adaptive Distribution Partners For Cell And Gene TherapiesOptimize your commercial strategy by exploring how adaptive distribution models navigate reimbursement challenges and improve patient access. Partner early to align workflows and ensure operational success.
-
![GettyImages-521848481 clinical trial, patient, diversity]( "Partnering With Health Systems: Essential Tips For CGT Commercialization")
Partnering With Health Systems: Essential Tips For CGT CommercializationSuccessful cell and gene therapy commercialization requires early, detailed manufacturer collaboration with health systems to ensure scalable operations and seamless patient access beyond the clinical trial.
-
![GettyImages-1480473800 roadmap]( "Navigating Commercial Logistics For CGTs: A Roadmap To Scalable, Patient-Centered Success")
Navigating Commercial Logistics For CGTs: A Roadmap To Scalable, Patient-Centered SuccessThe commercialization of cell and gene therapies requires a precise and resilient logistics model that can adapt to rapid demand and global expansion while maintaining a patient-first approach.
-
![GettyImages-1323467662 data, meeting, strategy]( "Don't Let Distribution Derail Your CGT Launch")
Don't Let Distribution Derail Your CGT LaunchOvercoming distribution challenges is critical for the success of cell and gene therapies. Learn how to build a flexible, robust strategy to optimize patient access.
